FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology. Disclosed is use of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol for treating HER2-positive tumors experimentally in dose of 15–20 mg/kg parenterally.
EFFECT: in mice FVB/N with spontaneous or transplantable HER2-positive breast cancer 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (intraperitoneally) once caused partial and even complete temporary regression of tumor; invention extends the range of products for treating HER2-positive tumors, increases the therapeutic effect in suppressing tumor growth.
1 cl, 2 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL ORALLY FOR THE TREATMENT OF MELANOMA B16, EHRLICH TUMOR, SARCOMA 180, SARCOMA 37, LYMPHOSARCOMA LIO-1 AND CARCINOSARCOMA WALKER 256 EXPERIMENTALLY IN MICE AND RATS | 2020 |
|
RU2733643C1 |
| METHOD OF SYNTHESIS 2-[3-(2-CHLORETHYL)-3-NITROSOUREIDO]-1,3-PROPANE-DIOL OWNED WITH ANTITUMOR ACTIVITY | 2018 |
|
RU2678846C1 |
| USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL IN TREATING MALIGNANT EYE SOCKET TUMOURS IN EXPERIMENT IN MICE WITH TRANSPLANTED INTRAORBITAL EHRLICH CARCINOMA | 2023 |
|
RU2815639C1 |
| APPLICATION OF COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1.3-PROPANEDIOL FOR TREATMENT OF EHRLICH CARCINOMA, SARCOMA 37, LIO-1 LYMPHOSARCOMA, MELANOMA B16, TRANSPLANTED INTO LOWER EYELID OF MICE IN EXPERIMENT | 2020 |
|
RU2752083C1 |
| 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL SHOWING ANTITUMOR ACTIVITY | 1992 |
|
RU2068843C1 |
| 5-OXYMETHYL-5-[3-(2-CHLORETHYL)-3- NITROZOUREIDO]-2-CYCLOHEXYL- 1 | 2000 |
|
RU2179555C1 |
| NEW METHOD FOR SYNTHESIS OF 3-O-SULPHAMATE 16,16-DIMETHYL-D-HOMOEQUILENINE | 2021 |
|
RU2752064C1 |
| 3-O-SULFAMOILOXY-6-OXA-7Β-METHYL-D-HOMO-8Α-ESTRA-1,3,5(10)-TRIEN-17Α-ONE APPLICATION FOR THE BREAST CANCER TREATMENT, INCLUDING THE TRIPLE NEGATIVE FORM, AND ITS PRODUCTION METHOD | 2018 |
|
RU2679625C1 |
| APPLICATION OF 3-O-SULFAMATE-16,16-DIMETHYL-D-HOMOEQUILININE FOR TREATMENT OF ONCOLOGICAL DISEASES | 2018 |
|
RU2680603C1 |
| USE OF 3-O-SULFAMOYLOXY-7Β-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE FOR THE TREATMENT OF BREAST CANCER, INCLUDING A TRIPLE NEGATIVE FORM | 2018 |
|
RU2678845C1 |
